RPL17 and cancer: For example, Nivolumab, Pembrolizumab, Cemiplimab and Dostarlimab target PD-1 and inhibit their interaction with PDL-1 expressed on cancer cells as well as on non-cancer cells in the tumor microenvironment (TME).